Category: GeoVax Recent News
-
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide ATLANTA, GA, April 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today highlighted the urgent challenges caused by the supply-constrained, global orthopoxvirus vaccine market and outlined…
-
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen ATLANTA, GA, April 2, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today highlighted preclinical data presented at the World Vaccine Congress Washington 2026 supporting the potential for a single-dose Modified Vaccinia Ankara (MVA)-based mpox…
-
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA – March 31, 2026 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today announced its entry into a warrant inducement agreement with existing healthcare-focused institutional investors of the Company for the immediate exercise of existing warrants (the “Existing Warrants”) to purchase…
-
GeoVax Provides Update on GEO-MVA Program
Clinical Product Release Testing Completed in Support of Pivotal Phase 3 Trial Atlanta, GA – March 25, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today provided a development update on its GEO-MVA vaccine program for protection against mpox and smallpox, highlighting continued progress…
-
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable Populations ATLANTA, GA – March 12, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors, today announced the publication of a peer-reviewed…
-
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
Program Reaches Strategic Inflection Point as GEO-MVA Advances Toward Pivotal Phase 3 Study Atlanta, GA – March 11, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today announced that it has begun engaging with global health and preparedness organizations to explore potential future procurement…
-
GeoVax Announces Oncology Advisory Board to Advance Gedeptin® Development Across Solid Tumors
Members Bring Deep Expertise in Immuno-Oncology, Translational Medicine, and Checkpoint Inhibitor Combination Strategies ATLANTA, GA – February 24, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancers and infectious diseases, today announced the formation of its Oncology Advisory Board with the appointment of three internationally recognized leaders in…
-
GeoVax Secures Exclusive License for Gedeptin® + Immune Checkpoint Inhibitor Combination Technology
License Strengthens GeoVax’s Immuno-Oncology Strategy and Expands Intellectual Property Foundation for Combination Therapies Across Solid Tumors ATLANTA, GA – February 18, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has entered into an exclusive worldwide license agreement with Emory University…
-
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far from Over
Company Highlights GEO-MVA Manufacturing Readiness and Clear Clinical Pathway to Support Global Supply Diversification ATLANTA, GA – February 17, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today issued a statement endorsing the urgent call to action articulated by Rosamund Lewis, MD (WHO Head,…
-
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ATLANTA, GA, February 13, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX) (the “Company”), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into definitive agreements for the purchase and sale of 432,902 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase…
-
GeoVax Highlights 2026 as a Pivotal Year for Progress
Management Highlights 2026 as a Portfolio-Wide Inflection Year Driven by Regulatory De-Risking, Clinical Readouts, and Scalable Manufacturing ATLANTA, GA – January 20, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today provided a post-conference update following the J.P. Morgan Healthcare Conference Week in San…
-
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Atlanta, GA, January 8, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company’s Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a…